Syneron Announces the Launch of elure(TM) Advanced Skin Whitening Technology in Singapore
07 Noviembre 2010 - 11:01PM
PR Newswire (Canada)
YOKNEAM, Israel, Nov. 8, 2010 /CNW/ -- Today Syneron Medical Ltd.
(Nasdaq: ELOS), http://www.syneron.com, announces the initial
commercial launch in Singapore of elure(TM) Advanced Skin Whitening
Technology, the first and only skin lightening product that works
by directly breaking down melanin - the molecule that accumulates
in the skin to cause a darkened appearance. This novel targeted
mechanism of action found only in elure provides the pathway for a
meaningful improvement in the skin's tone, texture and radiance in
as little as seven days. More than this, elure lightens the skin
without the commonly reported side effects of traditional skin
lightening products, such as skin irritation. "elure is a much
anticipated breakthrough in skin lightening," said Vivian W. Bucay,
MD, US dermatologist and renowned skincare expert. "Now my patients
and their friends can experience very visible results in just a
matter of days." The organically-based active ingredient of elure
was developed after almost 30 years of research on a naturally
occurring enzyme. "Lignin peroxidase, the active ingredient of
elure, is a natural enzyme derived from a mushroom that grows on
trees called Phanerochaete chrysosporium," said Yoram Karmon, PhD,
one of the pioneer researchers of elure that also included Paula
Belinky, MD, from Migal Galilee Technological Center in Kiryat
Shmona, and Carlos Dosoretz, PhD, from the Technion-Israel
Institute of Technology in Haifa. "Our research confirmed that
lignin peroxidase uniquely breaks down or depolymerizes melanin in
human skin." In clinical trials using elure, Alain Khaiat, PhD,
President of the Cosmetic Toiletries and Fragrance Association of
Singapore and a 30-year veteran in skincare product development,
noted, "The safety and tolerability of elure is unparalleled. We
tested the product at 17,000 times the recommended human dose and
saw no potential for adverse events." Shimon Eckhouse, MD, Chairman
and co-founder of Syneron commented, "The first commercial launch
of elure in Asia marks an extremely important milestone for
Syneron, entering one of the largest world cosmetic markets with a
unique, patented product. This milestone emphasizes our strategy of
serving all of our customer needs in the areas of aesthetic
medicine with safe and effective breakthrough products." In the
Southeast Asian countries of Singapore, Malaysia and Indonesia,
elure will be marketed by Elure Singapore Pte. Ltd. For more
information about elure, visit www.elureskin.com. About Syneron
Medical Ltd. Syneron Medical Ltd. - a company devoted to real
technology, real science and real results - is the leading global
aesthetic device company with a comprehensive product portfolio and
a global distribution footprint. The Company's technology enables
physicians to provide advanced solutions for a broad range of
medical-aesthetic applications including body contouring, hair
removal, wrinkle reduction, rejuvenation of the skin's appearance
through the treatment of superficial benign vascular and pigmented
lesions, and the treatment of acne, leg veins and cellulite. The
Company sells its products under two distinct brands, Syneron and
Candela. With its innovative approach to aesthetic treatments,
Syneron has now entered into one of the largest in-demand
applications, skin lightening. Founded in 2000, the corporate,
R&D, and manufacturing headquarters for Syneron Medical Ltd.
are located in Israel. Syneron also has R&D and manufacturing
operations in the US. The company markets and services and supports
its products in 86 countries. It has offices in North America,
France, Germany, Italy, Portugal, Spain, UK, Australia, China,
Japan, and Hong Kong and distributors worldwide. Additional
information can be found at www.syneron.com. SAFE HARBOR FOR
FORWARD-LOOKING STATEMENTS Any statements contained in this
document regarding future expectations, beliefs, goals, plans or
prospects constitute forward-looking statements within the meaning
of the Private Securities Litigation Reform Act of 1995. Further,
any statements that are not statements of historical fact
(including statements containing "believes," "anticipates,"
"plans," "expects," "may," "will," "would," "intends," "estimates"
and similar expressions) should also be considered to be
forward-looking statements. There are a number of important factors
that could cause actual results or events to differ materially from
those indicated by such forward-looking statements, including the
risk that the businesses of Syneron and Candela may not be
integrated successfully; the risk that the merger transaction with
Candela may involve unexpected costs or unexpected liabilities; the
risk that synergies from the merger transaction may not be fully
realized or may take longer to realize than expected; the risk that
disruptions from the merger transaction make it more difficult to
maintain relationships with customers, employees, or suppliers; as
well as the risks set forth in Syneron Medical Ltd.'s most recent
Annual Report on Form 20-F, and the other factors described in the
filings that Syneron Medical Ltd. makes with the SEC from time to
time. If one or more of these factors materialize, or if any
underlying assumptions prove incorrect, Syneron Medical Ltd.'s
actual results, performance or achievements may vary materially
from any future results, performance or achievements expressed or
implied by these forward-looking statements. In addition, the
statements in this document reflect the expectations and beliefs of
Syneron Medical Ltd. as of the date of this document. Syneron
Medical Ltd. anticipates that subsequent events and developments
will cause its expectations and beliefs to change. However, while
Syneron Medical Ltd. may elect to update these forward-looking
statements publicly in the future, it specifically disclaims any
obligation to do so. The forward-looking statements of Syneron
Medical Ltd. do not reflect the potential impact of any future
dispositions or strategic transactions that may be undertaken.
These forward-looking statements should not be relied upon as
representing Syneron Medical Ltd.'s views as of any date after the
date of this document. Contact: Tom Albright President and General
Manager Topical Aesthetic Division, Syneron Medical Ltd. Office:
949-716-6670 (Extension 235) Cell: 949-632-9226
talbright@syneron.com Jane W. Smith Director of Marketing
Communications Candela Corporation Office: 508-358-7637 (Extension
247) Cell: 978-314-1053 jane.smith@candelalaser.com Tom Albright,
President and General Manager, Topical Aesthetic Division, Syneron
Medical Ltd., +1-949-716-6670 Extension 235, Cell: +1-949-632-9226,
talbright@syneron.com, or Jane W. Smith, Director of Marketing
Communications, Candela Corporation, +1-508-358-7637 Extension 247,
Cell: +1-978-314-1053, jane.smith@candelalaser.com Web Site:
http://www.syneron.com
Copyright
Syneron Medical Ltd. - Ordinary Shares (NASDAQ:ELOS)
Gráfica de Acción Histórica
De Jun 2024 a Jul 2024
Syneron Medical Ltd. - Ordinary Shares (NASDAQ:ELOS)
Gráfica de Acción Histórica
De Jul 2023 a Jul 2024